Identification of protein biomarkers in Dupuytren's contracture using Surface Enhanced Laser Desorption Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS)

Clinical and Investigative Medicine

Volumn 29, Issue 3, 2006, Pages 136-145

  O'Gorman, David ^a,b,c,d,e   Howard, Jeffrey C ^a,b   Varallo, Vincenzo M ^a,b   Cadieux, Peter ^c,e   Bowley, Erin ^a,b,c   McLean, Kris ^a,b,c,d,e   Pak, Brian J ^f   Gan, Bing Siang ^a,b,c,d,e,g  

^a Cell and Molecular Biology Laboratory   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d Department of Surgery ^*  (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f CIPHERGEN BIOSYSTEMS INC   (United States)

^g ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ALGORITHMS; BIOLOGICAL MARKERS; DUPUYTREN CONTRACTURE; DUPUYTREN'S CONTRACTURE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; PROTEIN ARRAY ANALYSIS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33745284301     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rayan GM. Clinical presentation and types of Dupuytren's disease. Hand Clin. 1999;15:87-96.
2. Gudmundsson KG, Arngrimsson R, Sigfusson N, Bjornsson A, Jonsson T. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol. 2000;53:291-6.
3. Yi IS, Johnson G, Moneim MS. Etiology of Dupuytren's disease. Hand Clin. 1999;15:43-51.
4. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-33.
5. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, Narayan D. Microarray gene analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg. 2003;50:618-22.
6. Bayat A, Watson JS, Stanley JK, et al. Genetic susceptibility in Dupuytren's disease. TGF-beta1 polymorphisms and Dupuytren's disease. J Bone Joint Surg Br. 2002;84:211-5.
7. Bayat A, Stanley JK, Watson JS, Ferguson MW, Ollier WE. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. Br J Plast Surg 2003;56:328-33.
8. Bayat A, Watson JS, Stanley JK, Ferguson MW, Ollier WE. Genetic susceptibility to dupuytren disease: association of Zf9 transcription factor gene. Plast Reconstr Surg 2003;111:2133-9.
9. Kim Y, Ratziu V, Choi SG, et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 1998;273:33750-8.
10. Ratziu V, Lalazar A, Wong L, et al. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci USA 1998;95:9500-5.
11. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-77.
12. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
13. Cadieux PA, Beiko DT, Watterson JD, et al. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal 2004;18:170-5.
14. Wadsworth JT, Somers KD, Stack BC, Jr., et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130:98-104.
15. Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol 2004;10:2327-9.
16. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
17. Howard JC, Heinemann C, Thatcher BJ, Martin B, Gan BS, Reid G. Identification of collagen-binding proteins in Lactobacillus spp. with surface-enhanced laser desorption/ionization-time of flight ProteinChip technology. Appl Environ Microbiol 2000;66:4396-400.
18. Reid G, Gan BS, She YM, Ens W, Weinberger S, Howard JC. Rapid identification of probiotic lactobacillus biosurfactant proteins by ProteinChip tandem mass spectrometry tryptic peptide sequencing. Appl Environ Microbiol 2002;68:977-80.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
20. Saar JD, Grothaus PC. Dupuytren's disease: an overview. Plast Reconstr Surg. 2000;106:125-134.
21. Elliot D. The early history of Dupuytren's disease. Hand Clin. 1999;15:1-19..
22. Jabaley ME. Surgical treatment of Dupuytren's disease. Hand Clin. 1999;15:109-26,
23. Nyberg LM, Jr., Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Uro. 1982;128:48-51.
24. Wilbrand S, Ekbom A, Gerdin B. Dupuytren's contracture and sarcoma. J Hand Surg 2002;27:50-2.
25. Wilbrand S, Ekbom A, Gerdin B. Cancer incidence in patients treated surgically for Dupuytren's contracture. J Hand Surg [Br].2000;25:283-7.
26. Bains W. Vasoprotective VEGF as a candidate for prevention of recurrence of fibrotic diseases such as Dupuytren's contracture. Med Hypotheses. 2003;60:793-6.
27. Fitzgerald AM, Kirkpatrick JJ, Naylor IL. Dupuytren's Disease. The way forward? Journal of Hand Surgery. 1999;24B:395-9.
28. Mehta AI, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers. 2003;19:-10.
29. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.
30. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
31. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609-14.
32. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-7.